Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS
Date:5/7/2013

this press release.

In May 2013, our board of directors authorized the use of up to $200 million to repurchase the company's ordinary shares. The timing and amount of repurchases will depend on a variety of factors, including the price of the company's ordinary shares, alternative investment opportunities, restrictions under our existing credit agreement, corporate and regulatory requirements and market conditions. 

First Quarter 2013 Revenues and Product SalesTotal revenues for the first quarter of 2013 were $196.2 million, compared to total revenues of $102.5 million for the first quarter of 2012. The increase in total revenues for the quarter ended March 31, 2013 was driven primarily by inclusion of revenues from the acquired EUSA Pharma business and increased net sales of Xyrem® (sodium oxybate) oral solution.

Total revenues for the quarter ended March 31, 2013 included net sales, royalties and contract revenues. A table showing net sales for the first quarter of 2013 compared to pro forma net sales for the first quarter of 2012 is included in this press release.

Net sales for the first quarter of 2013 were as follows:

  • Xyrem®:  First quarter 2013 Xyrem sales increased by 60% to $117.5 million compared to $73.4 million during the first quarter of 2012.  During the first quarter of 2013, the average number of active Xyrem patients was approximately 10,550.
  • Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi):  First quarter 2013 worldwide net sales of Erwinaze/Erwinase were $41.8 million compared to first quarter 2012 pro forma net sales of $32.9 million. 
  • Prialt® (ziconotide) intrathecal infusion:  First quarter 2013 net sales of Prialt were $5.0 million compared to pro forma net sales of $9.9 million in the same period of 2012.  The higher pro forma net s
    '/>"/>

  • SOURCE Jazz Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock
    2. Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy
    3. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
    4. Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
    5. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
    6. Valeant Pharmaceuticals Provides Efinconazole Update
    7. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
    8. Cumberland Pharmaceuticals Reports First Quarter Financial Results
    9. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    10. Webcast Alert: Isis Pharmaceuticals First Quarter 2013 Financial Results Conference Call
    11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
    (Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
    (Date:7/25/2014)... HILL, N.C. , July 25, 2014  Corporate ... challenges, including understanding new advancements in technology and how ... of this, libraries in the pharmaceutical and medical device ... value of the information and services they provide. ... Best Practices, LLC there are many forces of change ...
    Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6Forces of Change Reshaping Corporate Libraries & Information Services 2
    ... on 01/05/2012 of Santa Barbara physician Dr. Julio Diaz ... overdose deaths from prescription medications. According to one of ... centers, Dr. Diaz,s arrest points to the dangers both ... of finding a physician who will prescribe medication for ...
    ... PHILADELPHIA, January 10, 2012 Shire plc (LSE: ... company, announced today that it has acquired the rights to ... States (US) in an agreement  with Janssen Pharmaceutica N.V.  Terms ... a prokinetic, is part of Shire,s gastrointestinal (GI) portfolio in ...
    Cached Medicine Technology:Arrest of California Doctor Coincides with Uptick in Prescription Drug Overdoses 2Shire Acquires US Rights to Resolor® (prucalopride) 2Shire Acquires US Rights to Resolor® (prucalopride) 3Shire Acquires US Rights to Resolor® (prucalopride) 4
    (Date:7/28/2014)... researchers in Taiwan has developed a new optical technology ... of diabetes sooner, when it is more easily treated. ... trials, it may pave the way for the early ... diabetic autonomic neuropathy, which is common among people with ... progressively affects the autonomic nerves controlling vital organs like ...
    (Date:7/28/2014)... (PRWEB) July 28, 2014 Top Northridge ... coupon for new patients. Finding a new dentist can be ... dental issues that have gone untreated and worry about how ... Ariz specializes in patients with special concerns and dental needs ... comfortable and right at home. This special coupon can help ...
    (Date:7/28/2014)... July 28, 2014 "I injured my shoulder ... said an inventor from Sunnyvale, Calif. "When I slept in ... the market are cumbersome and require too many straps. That ... developed the Multiple Functioning Vest to improve the design of ... so that they heal properly. This helps to speed up ...
    (Date:7/28/2014)... HealthDay Reporter FRIDAY, July ... health insurance this year will face fines of up to ... the Internal Revenue Service says. The Obama administration on ... that some Americans will owe for failing to have health ... monthly national average premium for a bronze-level health plan. ...
    (Date:7/28/2014)... 2014 Glidewell Laboratories announced today that ... successfully passed the five-year mark in clinical usage, and ... units prescribed by US dentists. , Even as BruxZir ... good results from respected clinical studies, many dentists expressed ... over extended years of clinical service before they would ...
    Breaking Medicine News(10 mins):Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:IRS Caps Fines on Uninsured Americans at $12K for Family of 5 2Health News:BruxZir® Solid Zirconia Surpasses Five Years of Clinical Use 2
    ... , HARRISBURG, Pa. , Jan. 13 ... launch of an innovative initiative to create clinically proven, ... of care for patients.  The P4 Pathways Program will ... for the treatment of patients with cancer, as well ...
    ... , NEW YORK , Jan. 13 ... been named president and CEO of Siemens Corporation. Spiegel, an ... on January 18 . , (Logo:   http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ... Senior Partner at Booz & Co. and brings more than ...
    ... Bradley C. Brennecke , a resident of Pleasant Plain, Ohio ... , pleaded guilty late Tuesday to conspiracy and tax evasion charges before District ... Department and Internal Revenue Service (IRS) announced. , Mrusek and Brennecke, who ... icted in July 2009 and charged with tax ...
    ... in the general population use the drug responsibly, study finds ... taking Viagra will lead to sexually risky behavior can relax: ... make men more likely to engage in potentially unhealthy sex. ... a doctor who may worry that prescribing erectile-dysfunction drugs to ...
    ... say researchers working with mice , WEDNESDAY, Jan. 13 ... greater understanding of how a brain becomes susceptible to ... some people are resistant to antidepressants. , Scientists think ... -- cause the mental disorders. Antidepressants (such as Prozac) ...
    ... aged 6-19 still climbing, government study finds , WEDNESDAY, Jan. ... on weight: Obesity in the United States may finally be ... the rates of obesity remain high, with about one-third of ... obesity among already heavy 6- to 19-year-old boys appear to ...
    Cached Medicine News:Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 2Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 3Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 4Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 2Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 3Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News:Taking Viagra Won't Spur Risky Sexual Behavior 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3
    Duckbill. 3.5 mm tip. Light curve....
    4 mm x 9 mm tip....
    6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
    9 mm wide tip. 35 mm from angle to tip....
    Medicine Products: